Related Experiment Video
Updated: Jul 9, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Azathioprine in dermatology.
Ivana Bardek1, Visnja Milavec-Puretić, Jasna Lipozencić
1University Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine, Salata 4, HR-10000 Zagreb, Croatia. ivanabardek@yahoo.com
Acta Dermatovenerologica Croatica : ADC
|December 21, 2007
Summary
Azathioprine, a purine analog, treats immune-related skin conditions. Measuring thiopurine s-methyltransferase (TPMT) activity before treatment ensures safe and effective azathioprine dosing.
Area of Science:
- Immunodermatology
- Pharmacology
- Biochemistry
Background:
- Azathioprine is a synthetic purine analog with cytotoxic and immunosuppressive properties.
- It is utilized in dermatology for treating immunobullous diseases, eczematous disorders, and photodermatoses.
Purpose of the Study:
- To elucidate the mechanism of action of azathioprine.
- To highlight the importance of thiopurine s-methyltransferase (TPMT) activity assessment for azathioprine therapy.
Main Methods:
- Review of azathioprine's mechanism as a purine antagonist.
- Identification of TPMT's role in azathioprine metabolism.
Main Results:
- Azathioprine's active metabolites disrupt endogenous purine function.
- TPMT enzyme activity is critical for azathioprine metabolism and effective dosing.
Conclusions:
- Azathioprine is an effective immunosuppressant for various dermatological conditions.
- Pre-treatment TPMT activity measurement is essential for optimizing azathioprine dosage and patient safety.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:23Skin Diseases and Disorders
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...